Aerie Pharmaceuticals, Inc. - Common Stock (NQ:AERI)

N/A UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 18, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Aerie Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 Next >

Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

November 22, 2022

From Alcon Inc. Investors

Via Business Wire

Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

November 03, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI

October 14, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Small-Cap Catalyst Pharma Is Among Market's Best Price Performers

October 04, 2022

Small-cap biotech Catalyst Pharmaceuticals has been outperforming the broader market amid earnings and revenue acceleration. It joined the S&P 600 last month.

Via MarketBeat

Topics Stocks

Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options

September 13, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

August 24, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

AERI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of Aerie Pharmaceuticals, Inc. Is Fair to Shareholders

August 24, 2022

From Halper Sadeh LLP

Via Business Wire

Aerie Pharmaceuticals (NASDAQ: AERI) Enters into Agreement to be Acquired by Alcon (NYSE: ALC) for $770 Million

August 23, 2022

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) is engaged within the research, development and commercialization of ophthalmic therapies for the treatment of

Via Spotlight Growth

Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

August 22, 2022

From Alcon Inc. Investors

Via Business Wire

Aerie Pharmaceuticals Announces New Employee Inducement Grant

August 15, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

August 04, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Announces First Participant Dosed in the COMET-3 Study of AR-15512 for the Treatment of Dry Eye Disease

August 01, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on Thursday, August 4, 2022 at 5:00 p.m. ET

July 28, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Announces New Employee Inducement Grant

July 08, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Participate in the Jefferies Healthcare Conference on Friday, June 10, 2022 at 10:30 a.m. ET

May 25, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Announces First Participant Dosed in the Phase 3 Registrational COMET-2 Study of AR-15512 for the Treatment of Dry Eye Disease

May 24, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

May 05, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on Thursday, May 5, 2022 at 5:00 p.m. ET

April 28, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Announces Presentations at the Association for Research in Vision and Ophthalmology Annual Meeting in Denver, Colorado, May 1-4, 2022

April 26, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Announces Presentations at the American Society of Cataract and Refractive Surgery (ASCRS 2022) in Washington, D.C., April 22-26, 2022

April 20, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 3:00 p.m. ET

April 06, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer

March 18, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

February 24, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Appoints Gary Sternberg, M.D., M.B.A. as Chief Medical Officer

February 24, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on Thursday, February 24, 2022 at 5:00 p.m. ET

February 17, 2022

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Reports Inducement Grant to Chief Executive Officer Under Nasdaq Listing Rule 5635(c)(4)

December 22, 2021

From Aerie Pharmaceuticals

Via Business Wire

Aerie Pharmaceuticals Appoints Raj Kannan as Chief Executive Officer

December 16, 2021

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Regions

December 07, 2021

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

November 09, 2021

From Aerie Pharmaceuticals, Inc.

Via Business Wire

Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

November 04, 2021

From Aerie Pharmaceuticals, Inc.

Via Business Wire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.